Zentalis Pharmaceuticals, Inc. Sublease Income
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Sublease Income of $300.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. sublease income for the quarter ending 2026-06-30 was $300.00K.
- Zentalis Pharmaceuticals, Inc. sublease income for the quarter ending 2026-03-31 was $400.00K, a 0.00% change year-over-year.
- Zentalis Pharmaceuticals, Inc. sublease income for the quarter ending 2025-12-31 was $300.00K, a 0.00% change year-over-year.
- Zentalis Pharmaceuticals, Inc. sublease income for the quarter ending 2025-09-30 was $700.00K, a 75.00% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. sublease income for fiscal 2025 was $1.40M, a 0.00% change from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. sublease income for fiscal 2024 was $1.40M, a 55.56% increase from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. sublease income for fiscal 2023 was $900.00K.
| Period end | Sublease Income 3 month | Sublease Income 6 month | Sublease Income 9 month | Sublease Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $300.00K 10-Q · filed 2026-08-06 | $700.00K 10-Q · filed 2026-08-06 | $1.00M derived: sum of 3 quarters · filed 2026-08-06 | $1.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $400.00K 10-Q · filed 2026-05-12 | $700.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.40M derived: sum of 3 quarters · filed 2026-05-12 | $1.40M derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.00M derived: sum of 2 quarters · filed 2026-03-26 | $1.00M derived: sum of 3 quarters · filed 2026-03-26 | $1.40M 10-K · filed 2026-03-26 |
| 2025-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $700.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.10M 10-Q · filed 2025-11-10 | $1.40M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $400.00K 10-Q · filed 2025-08-06 | $700.00K derived: sum of 3 quarters · filed 2026-03-26 | $1.10M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $400.00K 10-Q · filed 2025-05-14 | $700.00K derived: sum of 2 quarters · filed 2026-03-26 | $1.10M derived: sum of 3 quarters · filed 2026-03-26 | $1.40M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $700.00K derived: sum of 2 quarters · filed 2026-03-26 | $1.00M derived: sum of 3 quarters · filed 2026-03-26 | $1.40M 10-K · filed 2026-03-26 |
| 2024-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $700.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.10M 10-Q · filed 2024-11-12 | $1.40M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $700.00K 10-Q · filed 2024-08-09 | $1.00M derived: sum of 3 quarters · filed 2024-08-09 | $1.40M derived: sum of 4 quarters · filed 2024-08-09 |
| 2024-03-31 | $400.00K 10-Q · filed 2024-05-07 | $700.00K derived: sum of 2 quarters · filed 2024-05-07 | $1.10M derived: sum of 3 quarters · filed 2024-05-07 | |
| 2023-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $700.00K derived: sum of 2 quarters · filed 2024-02-27 | $900.00K 10-K · filed 2024-02-27 | |
| 2023-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $600.00K 10-Q · filed 2023-11-06 | ||
| 2023-06-30 | $200.00K 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |